Drug · CHEMBL467
HYDROXYUREA
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. HYDROXYUREA. Drugs and targets, record CHEMBL467. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL467
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 5 of its 75 diseases, from ATC, DailyMed and EMA Human Drugs
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/6240 |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/6241 |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/50484 |
Source ChEMBL
Diseases75
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 75Source Open Targets
See all 75 diseasesTrials199
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01966731 | Realizing Effectiveness Across Continents With Hydroxyurea (REACH) | Phase 1/2 | 635 | 2020-11-09 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | Phase 2 | 317 | 2020-10-08 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT00117572 | Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) | Phase 3 | 285 | 2018-04-09 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | Phase 3 | 240 | 2011-02-02 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | Phase 2 | 231 | 2011-05-16 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT01976416 | Novel Use Of Hydroxyurea in an African Region With Malaria | Phase 3 | 208 | 2018-10-01 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT00006400 | Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | Phase 3 | 193 | 2020-08-19 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT01259856 | Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | Phase 3 | 168 | 2018-07-24 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT01425307 | Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea | Phase 3 | 159 | 2017-04-11 | hydroxyurea | Its name | ClinicalTrials.gov |
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients | Phase 4 | 150 | 2018-01-24 | hydroxyurea | Its name | ClinicalTrials.gov |
1 to 10 of 199
See all 199 trialsComparisons in its trials49
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: deaths from any cause | 39 of 138 | 42 of 135 | 273 | NCT00117572 | Trial comparisons |
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: serious adverse events | 65 of 138 | 38 of 135 | 273 | NCT00117572 | Trial comparisons |
| Imatinib 600 mg + Hydroxyurea 1000 mg vs Imatinib 1000 mg + Hydroxyurea 1000 mg: serious adverse events | 62 of 131 | 53 of 99 | 230 | NCT00290771 | Trial comparisons |
| Hydroxyurea vs Placebo: deaths from any cause | 2 of 104 | 1 of 103 | 207 | NCT01976416 | Trial comparisons |
| Hydroxyurea vs Placebo: serious adverse events | 6 of 104 | 6 of 103 | 207 | NCT01976416 | Trial comparisons |
| Hydroxyurea vs Placebo: deaths from any cause | 0 of 96 | 0 of 97 | 193 | NCT00006400 | Trial comparisons |
| Hydroxyurea vs Placebo: serious adverse events | 19 of 96 | 35 of 97 | 193 | NCT00006400 | Trial comparisons |
| PEGASYS vs Hydroxyurea: Number of Participants With Major Cardiovascular Events After Therapy | 1 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: deaths from any cause | 0 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: serious adverse events | 14 of 82 | 4 of 86 | 168 | NCT01259856 | Trial comparisons |
1 to 10 of 49
See all 49 comparisons in its trialsPapers from its trials126
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL467
GET https://conductscience.org/api/drugs/v1/CHEMBL467/diseases?page=2